News from boehringer ingelheim pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 06, 2015, 08:00 ET

FDA Files Supplemental New Drug Application for Boehringer Ingelheim's Pradaxa® (dabigatran etexilate mesylate) for the Prophylaxis of Deep Venous Thrombosis and Pulmonary Embolism After Hip Replacement Surgery

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) filed a supplemental New Drug...

Mar 20, 2015, 13:01 ET
K. Alexander Papp, MD, PhD

Boehringer Ingelheim's Investigational Biologic Cleared Skin Better than Ustekinumab in Head-to-Head Phase II Psoriasis Study

For the first time, Boehringer Ingelheim announced Phase II data from its investigational compound BI 655066[*]. Nearly double the percentage of...

Mar 16, 2015, 08:00 ET

New Data from Boehringer Ingelheim's GLORIA™-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients at High Risk of Stroke May Be Undertreated

 Boehringer Ingelheim Pharmaceuticals, Inc. today will present results from two analyses of the GLORIA™-AF Registry Program examining the...

Mar 02, 2015, 08:00 ET

Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced it has submitted a biologics license application (BLA) to the U.S. Food and Drug...

Feb 12, 2015, 09:19 ET

New Survey Uncovers Emotional and Physical Impact of Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease

 People living with idiopathic pulmonary fibrosis (IPF) lack understanding of the disease, experience significant emotional burden and feel...

Feb 10, 2015, 13:15 ET
http://www.multivu.com/players/English/7401451-boehringer-ingelheim-diabetes/gallery/image/b48463d6-1153-4c1a-82f8-d34d911b945a.HR.jpg

Boehringer Ingelheim Launches Groundbreaking Initiative "Cuida tu Don" with Entertainer "Don Francisco" Aimed at Hispanics with Type 2 Diabetes

 Today, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced the launch of 'Cuida tu Don,' a national public awareness initiative...

Feb 10, 2015, 08:00 ET

Boehringer Ingelheim lanza una iniciativa innovadora "Cuida tu Don" con el animador "Don Francisco", dirigido a hispanos con diabetes tipo 2

Hoy, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) anunció el lanzamiento de 'Cuida tu Don', una iniciativa de concientización...

Feb 02, 2015, 08:30 ET
Glyxambi® (empagliflozin/linagliptin) tablet packaging 10/5 mg (left). Glyxambi® (empagliflozin/linagliptin) tablet packaging 25/5 mg (right)

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer...

Jan 21, 2015, 09:02 ET
SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema, and to reduce exacerbations in COPD patients.

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray is now...

Dec 08, 2014, 13:30 ET

New Data Show Idarucizumab* Reverses Anticoagulant Effects of Dabigatran (PRADAXA®) in Middle-Aged, Elderly and Renally Impaired Volunteers

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I data that showed administration of investigational idarucizumab in healthy...

Nov 18, 2014, 10:00 ET

New Data Show Idarucizumab* Restores Wound-Site Formation of Fibrin, a Key Component of Blood Clotting, in Healthy Volunteers Given Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I study sub-analyses showing that its investigational antidote idarucizumab...

Nov 18, 2014, 10:00 ET

Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation

Brigham and Women's Hospital and Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim findings from an analysis of two health...

Nov 17, 2014, 10:00 ET

U.S. Department of Defense Study Supports Favorable Benefit-Risk Profile of Pradaxa® (dabigatran etexilate mesylate) for Reducing Stroke Risk in Non-valvular Atrial Fibrillation

Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System...

Nov 10, 2014, 08:00 ET

New Real-World Safety and Efficacy Data on Pradaxa® (dabigatran etexilate mesylate) to be Presented at American Heart Association Scientific Sessions

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that two separate comparative analyses evaluating the safety and efficacy of...

Nov 10, 2014, 08:00 ET

Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of U.S. sites of the RE-VERSE AD™ trial (NCT02104947), a phase...

Nov 03, 2014, 10:00 ET

Boehringer Ingelheim Announces U.S. Filing Acceptance of New Drug Application for Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Treatment of Asthma

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for...

Oct 27, 2014, 09:45 ET

Boehringer Ingelheim Presents Data for the Co-Administration of Two Approved Products for COPD Patients

 Boehringer Ingelheim today presented data from the ANHELTO™ 1&2 studies (NCT01694771/NCT01696058) that evaluated the...

Oct 15, 2014, 18:55 ET

FDA Approves Boehringer Ingelheim's OFEV® (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved OFEV® (nintedanib)...

Oct 08, 2014, 08:00 ET

New COPD Maintenance Treatment Striverdi® Respimat® (olodaterol) Inhalation Spray Now Available in U.S. Pharmacies

 Boehringer Ingelheim today announced that Striverdi® Respimat® (olodaterol) Inhalation Spray 5 mcg is now available by prescription...

Sep 29, 2014, 08:00 ET

Head-to-head Phase III trial demonstrates superior progression-free survival of afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

Phase III data from Boehringer Ingelheim's LUX-Lung 8 trial, the first study to evaluate the superiority of afatinib versus erlotinib in patients...